1. Cross S, Levi J, Venter F, Hill A, et al.
   The estimated cost of MK-8527 produced at scale for once-monthly oral HIV pre-exposure prophylaxis (PrEP) in low- and middle-income countries.
   AIDS 2026.
   


2. Mason J, Kohli M, Taiwo E, Maan I, et al.
   Switching to doravirine-based antiretroviral therapy without genotypic resistance tests in virologically suppressed people with HIV.
   AIDS 2026.
   


3. Giovenco D, Rousseau E, Wallace M, Bekker LG, et al.
   Unraveling PrEP persistence: mental health and substance use among adolescent girls and young women in a PrEP implementation program.
   AIDS 2026.
   


4. Garcia-Abellan J, Garcia JA, Padilla S, Fernandez-Gonzalez M, et al.
   Contribution of hepatic steatosis to subclinical atherosclerosis progression in people with HIV receiving integrase inhibitors: A 5-Year prospective cohort study.
   AIDS 2026.
   


5. Santerre M, Allen CNS, Arjona SP, Shcherbik N, et al.
   HIV-1 gp120 exposure associates with mitochondrial and PKM remodeling in cardiomyocytes.
   AIDS 2026.
   


6. Filip I.
   Can scientific innovation translate into real-world impact in the era of diversified HIV prevention choices?
   AIDS 2026.
   


7. Wada NI, Chen Y, Bullotta A, Suder-Egnot N, et al.
   Herpesvirus and GB Virus C Infections in Men With and Without HIV-1 Who Have Sex with Men.
   AIDS Res Hum Retroviruses 2026.
   


8. Foncillas A, Ambrosioni J, de la Mora L, Mallolas J, et al.
   Optimizing HBV Prevention When Switching to Long-Acting Cabotegravir/Rilpivirine.
   Clin Infect Dis 2026.
   


9. Rouget R, Valin N, Bachelard A, Palacios C, et al.
   Acute Hepatitis B among PWH Switched to Long-Acting Cabotegravir/Rilpivirine: The Context Matters.
   Clin Infect Dis 2026.
   


10. Roland KB, Borkowf CB, Teplinskiy I, Almirol E, et al.
    Implementation of health insurance navigation for racial/ethnic minority men who have sex with men presenting for community-based HIV testing.
    J Acquir Immune Defic Syndr 2026.
    


11. Jones MA, Erenrich RK, Taggart T, Talan AJ, et al.
    Adverse Childhood Experiences and Behaviors Associated with HIV Acquisition Among Adult Sexual Minority Men in the United States.
    J Acquir Immune Defic Syndr 2026.
    


12. Massanella M, Dufour C, Pagliuzza A, Lemieux A, et al.
    Rapid and profound decay of inducible and intact HIV genomes in early treated Thai children.
    J Clin Invest 2026.
    


13. Gotthold Z, Epstein-Shuman A, Kigozi G, Lamers SL, et al.
    Pre-ART Vertical HIV-1 Transmission Risk in Uganda Varies by Sex of Child and Maternal Viral Subtype.
    J Infect Dis 2026.
    


14. Koberssy Z, Daher J, Durieux JC, Atieh O, et al.
    Comparison of Immune Activation and Gut Barrier Dysfunction between Long COVID and HIV infection.
    J Infect Dis 2026.
    


15. Rallon N, Restrepo C, Manquillo A, Perez-Sanchez C, et al.
    Distinctive Inflammatory Proteomic Profile of HIV-1 Elite Controllers: A Comparative Study in a Spanish Cohort.
    J Med Virol 2026;98:e70901.
    


16. Konan B, Segla R, Ong H, de Mendoza C, et al.
    Infection With Human T-Lymphotropic Virus 1 (HTLV-1) in Ivory Coast.
    J Med Virol 2026;98:e70892.
    


17. Passerini S, Mariotti D, Messina S, Mazzotta V, et al.
    Prevalence and Molecular Profiling of Merkel Cell Polyomavirus in Patients With Monkeypox Virus Infection.
    J Med Virol 2026;98:e70890.
    


18. Cheng D, Luo Z, Ning W, Heath SL, et al.
    Systemic translocation of Staphylococcus aureus promotes autoimmunity: implications in autoantibody-mediated poor immune reconstitution from antiretroviral therapy in HIV.
    J Virol 2026.
    


19. Murphy T, Kelly M, Shimagaki KS, DeStefanis T, et al.
    Dual role of glycosylation in resistance to CD4-binding site broadly neutralizing antibodies.
    J Virol 2026.
    


20. Nachum GS, Boucher JI, Flynn JM, Quansah P, et al.
    Mutational scan of self-cleavage by HIV-1 protease provides new views of a conformationally dynamic mechanism.
    J Virol 2026.
    


21. Cohen J.
    Is a heralded U.S. effort to help the world battle HIV facing extinction?
    Science 2026;392:15-16.
    


22. Schutz E.
    HIV/AIDS: MSF condemns Gilead for refusing to sell it lenacapavir.
    BMJ 2026;393:s651.
    

Display articles in

• Abstract format